These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 14529477)

  • 1. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.
    Arts J; de Schepper S; Van Emelen K
    Curr Med Chem; 2003 Nov; 10(22):2343-50. PubMed ID: 14529477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
    Marson CM
    Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors in myelodysplastic syndrome.
    Bhalla K; List A
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: from target to clinical trials.
    Kelly WK; O'Connor OA; Marks PA
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1695-713. PubMed ID: 12457432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors: latest developments, trends and prospects.
    Moradei O; Maroun CR; Paquin I; Vaisburg A
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):529-60. PubMed ID: 16178777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view.
    Vanhaecke T; Papeleu P; Elaut G; Rogiers V
    Curr Med Chem; 2004 Jun; 11(12):1629-43. PubMed ID: 15180568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors in cancer therapy.
    Rasheed WK; Johnstone RW; Prince HM
    Expert Opin Investig Drugs; 2007 May; 16(5):659-78. PubMed ID: 17461739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: gathering pace.
    Carey N; La Thangue NB
    Curr Opin Pharmacol; 2006 Aug; 6(4):369-75. PubMed ID: 16781195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.